NMDA receptor antagonists: Repositioning of memantine as a multitargeting agent for Alzheimer's therapy

Md Tanvir Kabir; Mohammad A. Sufian; Md Sahab Uddin; Mst Marium Begum; Shammi Akhter; Ariful Islam; Bijo Mathew; Md Siddiqul Islam; Md Shah Amran; Ghulam Md Ashraf

doi:10.2174/1381612825666191011102444

NMDA receptor antagonists: Repositioning of memantine as a multitargeting agent for Alzheimer's therapy

Md Tanvir Kabir, Mohammad A. Sufian, Md Sahab Uddin^*, Mst Marium Begum, Shammi Akhter, Ariful Islam, Bijo Mathew, Md Siddiqul Islam, Md Shah Amran, Ghulam Md Ashraf

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

84 Citations (Scopus)

Abstract

Alzheimer’s disease (AD) is a progressive neurodegenerative disease that causes problems with memory, thinking, and behavior. Currently, there is no drug that can reduce the pathological events of this degenerative disease but symptomatic relief is possible that can abate the disease condition. N-methyl-D-aspartate (NMDA) receptors exert a critical role for synaptic plasticity as well as transmission. Overstimulation of glutamate receptors, predominantly NMDA type, may cause excitotoxic effects on neurons and is recommended as a mechanism for neurodegeneration. Atypical activation of the NMDA receptor has been suggested for AD by synaptic dysfunction. NMDA receptor antagonists especially memantine block the NMDA receptor and can reduce the influx of calcium (Ca²⁺) ions into neuron, thus, toxic intracellular events are not activated. This review represents the role of NMDA receptors antagonists as potential therapeutic agents to reduce AD. Moreover, this review highlights the repositioning of memantine as a potential novel therapeutic multitargeting agent for AD.

Original language	English
Pages (from-to)	3506-3518
Number of pages	13
Journal	Current Pharmaceutical Design
Volume	25
Issue number	33
DOIs	https://doi.org/10.2174/1381612825666191011102444
Publication status	Published - 2019
Externally published	Yes

Keywords

Alzheimer’s disease
Amyloid beta
Glutamate receptors
Memantine
NMDA antagonists
Tau

Access to Document

10.2174/1381612825666191011102444

Cite this

@article{b109ced27ca448b08944d96920b1a197,

title = "NMDA receptor antagonists: Repositioning of memantine as a multitargeting agent for Alzheimer's therapy",

abstract = "Alzheimer{\textquoteright}s disease (AD) is a progressive neurodegenerative disease that causes problems with memory, thinking, and behavior. Currently, there is no drug that can reduce the pathological events of this degenerative disease but symptomatic relief is possible that can abate the disease condition. N-methyl-D-aspartate (NMDA) receptors exert a critical role for synaptic plasticity as well as transmission. Overstimulation of glutamate receptors, predominantly NMDA type, may cause excitotoxic effects on neurons and is recommended as a mechanism for neurodegeneration. Atypical activation of the NMDA receptor has been suggested for AD by synaptic dysfunction. NMDA receptor antagonists especially memantine block the NMDA receptor and can reduce the influx of calcium (Ca2+) ions into neuron, thus, toxic intracellular events are not activated. This review represents the role of NMDA receptors antagonists as potential therapeutic agents to reduce AD. Moreover, this review highlights the repositioning of memantine as a potential novel therapeutic multitargeting agent for AD.",

keywords = "Alzheimer{\textquoteright}s disease, Amyloid beta, Glutamate receptors, Memantine, NMDA antagonists, Tau",

author = "{Tanvir Kabir}, Md and Sufian, {Mohammad A.} and {Sahab Uddin}, Md and {Marium Begum}, Mst and Shammi Akhter and Ariful Islam and Bijo Mathew and {Siddiqul Islam}, Md and {Shah Amran}, Md and Ashraf, {Ghulam Md}",

note = "Publisher Copyright: {\textcopyright} 2019 Bentham Science Publishers",

year = "2019",

doi = "10.2174/1381612825666191011102444",

language = "English",

volume = "25",

pages = "3506--3518",

journal = "Current Pharmaceutical Design",

issn = "1381-6128",

number = "33",

}

TY - JOUR

T1 - NMDA receptor antagonists

T2 - Repositioning of memantine as a multitargeting agent for Alzheimer's therapy

AU - Tanvir Kabir, Md

AU - Sufian, Mohammad A.

AU - Sahab Uddin, Md

AU - Marium Begum, Mst

AU - Akhter, Shammi

AU - Islam, Ariful

AU - Mathew, Bijo

AU - Siddiqul Islam, Md

AU - Shah Amran, Md

AU - Ashraf, Ghulam Md

PY - 2019

Y1 - 2019

N2 - Alzheimer’s disease (AD) is a progressive neurodegenerative disease that causes problems with memory, thinking, and behavior. Currently, there is no drug that can reduce the pathological events of this degenerative disease but symptomatic relief is possible that can abate the disease condition. N-methyl-D-aspartate (NMDA) receptors exert a critical role for synaptic plasticity as well as transmission. Overstimulation of glutamate receptors, predominantly NMDA type, may cause excitotoxic effects on neurons and is recommended as a mechanism for neurodegeneration. Atypical activation of the NMDA receptor has been suggested for AD by synaptic dysfunction. NMDA receptor antagonists especially memantine block the NMDA receptor and can reduce the influx of calcium (Ca2+) ions into neuron, thus, toxic intracellular events are not activated. This review represents the role of NMDA receptors antagonists as potential therapeutic agents to reduce AD. Moreover, this review highlights the repositioning of memantine as a potential novel therapeutic multitargeting agent for AD.

AB - Alzheimer’s disease (AD) is a progressive neurodegenerative disease that causes problems with memory, thinking, and behavior. Currently, there is no drug that can reduce the pathological events of this degenerative disease but symptomatic relief is possible that can abate the disease condition. N-methyl-D-aspartate (NMDA) receptors exert a critical role for synaptic plasticity as well as transmission. Overstimulation of glutamate receptors, predominantly NMDA type, may cause excitotoxic effects on neurons and is recommended as a mechanism for neurodegeneration. Atypical activation of the NMDA receptor has been suggested for AD by synaptic dysfunction. NMDA receptor antagonists especially memantine block the NMDA receptor and can reduce the influx of calcium (Ca2+) ions into neuron, thus, toxic intracellular events are not activated. This review represents the role of NMDA receptors antagonists as potential therapeutic agents to reduce AD. Moreover, this review highlights the repositioning of memantine as a potential novel therapeutic multitargeting agent for AD.

KW - Alzheimer’s disease

KW - Amyloid beta

KW - Glutamate receptors

KW - Memantine

KW - NMDA antagonists

KW - Tau

UR - http://www.scopus.com/inward/record.url?scp=85074429321&partnerID=8YFLogxK

U2 - 10.2174/1381612825666191011102444

DO - 10.2174/1381612825666191011102444

M3 - Review article

C2 - 31604413

AN - SCOPUS:85074429321

SN - 1381-6128

VL - 25

SP - 3506

EP - 3518

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

IS - 33

ER -

NMDA receptor antagonists: Repositioning of memantine as a multitargeting agent for Alzheimer's therapy

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this